American Society of Hirudotherapy

Prurigo Nodularis (Investigational Adjunct)

Investigational adjunct for refractory prurigo nodularis; potent topical/intralesional steroids, gabapentinoids, and dupilumab (FDA-approved 2022) remain evidence-based.

Tier C — InvestigationalInvestigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Last Updated: November 10, 2026 · ASH Editorial · based on the books

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for prurigo nodularis. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
What evidence exists?
Tier C (investigational). No clinical study of leech therapy for prurigo nodularis was identified, so its effect is unknown. Evidence-based first-line management is high-potency topical corticosteroid under occlusion, intralesional triamcinolone, topical tacrolimus or cryotherapy for limited disease, and for moderate-to-severe disease dupilumab (FDA-approved 2022 for prurigo nodularis), nemolizumab, or other systemic options including gabapentinoids and antidepressants for itch control.
Main risks
  • Bleeding from each bite site for 6 to 10 hours after the leech detaches
  • Iron-deficiency anemia from cumulative blood loss across multiple sessions
  • Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
  • Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
  • Small Y-shaped bite marks or skin colour changes at the bite sites, which usually fade over weeks to months
  • Local pain, bruising, swelling, or itching for 1 to 3 days after each session
  • Itch worsening immediately after leech sessions
  • Aggravation of nodules by additional cutaneous inflammation
  • Triggering scratch-itch cycle relapse
Who should not consider this
  • Patients eligible for dupilumab who have not been offered it (FDA-approved for moderate-to-severe PN)
  • Patients without workup for underlying itch causes (renal disease, cholestasis, hematologic, atopic dermatitis)
  • Patients with poorly controlled atopic dermatitis or psoriasis driving the itch
  • Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran or heparin (daily aspirin alone is not a contraindication: tell your doctor, who starts with fewer leeches)
  • People with hemophilia or any other inherited bleeding disorder
  • Patients with anemia
  • People with an active infection at the planned application site
What to ask your clinician
  • Has dupilumab — the FDA-approved biologic for PN — been considered or tried?
  • Have I been worked up for systemic causes of itch (renal, liver, hematologic)?
  • Have I tried gabapentin or an antidepressant for the itch component?
  • What is the published evidence base for leeches in PN?
  • What is the risk that bites worsen itch or trigger more nodule formation?
  • How will treatment success be measured?
When to seek urgent care
  • Bleeding from a bite site that soaks through more than one dressing per hour
  • Bleeding that continues more than 24 hours after the leech detached
  • Spreading redness, warmth, swelling, pus, or red streaks around any bite site
  • Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
  • Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
  • Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
  • Spreading infection at nodule sites with fever
  • Sudden uncontrolled itch with new systemic symptoms (jaundice, weight loss, lymphadenopathy)

What this does NOT mean

  • It does not mean leech therapy is FDA-cleared for prurigo nodularis — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
  • It does not replace dupilumab, which IS FDA-approved for moderate-to-severe PN.
  • It does not address the scratch-itch cycle that perpetuates nodules.
  • It does not exclude or treat systemic causes of itch.
  • It does not have controlled-trial evidence in prurigo nodularis; no clinical study of leech therapy for it was identified.

Clinical Profile

Category
Dermatological
ICD-10
L28.1, L29.8
Safety tier
Medium

Evidence Summary

Prurigo nodularis is a chronic inflammatory dermatosis with hyperkeratotic, intensely pruritic nodules in the itch-scratch cycle. Evidence-based management includes potent topical or intralesional corticosteroids, calcineurin inhibitors, topical capsaicin, oral gabapentinoids or low-dose naltrexone for itch, phototherapy, and dupilumab (FDA-approved for moderate-to-severe prurigo nodularis in 2022). Nemolizumab (anti-IL-31RA) has positive phase III data. No clinical study or case report of hirudotherapy for prurigo nodularis was identified in PubMed, Europe PMC, Crossref or Russian- and German-language sources as of October 2026. The nearest leech data are small open-label eczema studies (Shankar 2014, 27 patients; Ulla P 2025, 20 patients), which did not include prurigo nodularis. Lesions are often on extensor surfaces in elderly patients with comorbid systemic disease.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)

Contraindications

  • Hemophilia or another bleeding disorder
  • Taking anticoagulants (blood thinners such as warfarin or heparin)
  • Anemia or suppressed blood formation
  • Low blood pressure, shock, collapse or fainting
  • Severe wasting (cachexia)
  • Intolerance of leeches or a history of severe allergic reactions
  • Pregnancy
  • Stomach or duodenal ulcer, erosive gastritis
  • Acute infectious disease or high fever
  • Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
  • Drinking alcohol at the time of treatment
  • No consent from the patient
  • Excoriated, infected, or actively oozing nodule
  • Underlying systemic itch cause not worked up (uremia, cholestasis, lymphoma)
  • Dupilumab eligible and accessible (use evidence-based therapy)
  • HIV or other immunocompromise where superinfection risk is high

Related Conditions

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.